A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 14,400 shares of CUE stock, worth $17,568. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,400
Previous 12,800 12.5%
Holding current value
$17,568
Previous $15,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$1.24 - $2.18 $78,069 - $137,250
-62,959 Reduced 43.05%
83,277 $103,000
Q1 2024

May 15, 2024

BUY
$1.77 - $3.09 $168,889 - $294,841
95,418 Added 187.76%
146,236 $276,000
Q4 2023

Feb 14, 2024

SELL
$1.72 - $3.1 $83,208 - $149,968
-48,377 Reduced 48.77%
50,818 $134,000
Q3 2023

Nov 14, 2023

BUY
$2.23 - $4.69 $26 - $56
12 Added 0.01%
99,195 $228,000
Q2 2023

Aug 14, 2023

SELL
$3.11 - $4.91 $20,140 - $31,797
-6,476 Reduced 6.13%
99,183 $362,000
Q1 2023

May 15, 2023

BUY
$2.41 - $3.74 $216,034 - $335,257
89,641 Added 559.63%
105,659 $377,000
Q4 2022

Feb 14, 2023

BUY
$2.39 - $3.95 $38,283 - $63,271
16,018 New
16,018 $45,000
Q2 2022

Aug 15, 2022

BUY
$2.49 - $5.92 $477,318 - $1.13 Million
191,694 Added 1552.3%
204,043 $508,000
Q1 2022

May 16, 2022

SELL
$4.41 - $12.28 $39,742 - $110,667
-9,012 Reduced 42.19%
12,349 $60,000
Q4 2021

Feb 14, 2022

SELL
$10.86 - $17.85 $4,278 - $7,032
-394 Reduced 1.81%
21,361 $0
Q2 2021

Aug 16, 2021

SELL
$10.9 - $14.53 $66,435 - $88,560
-6,095 Reduced 21.89%
21,755 $0
Q4 2020

Feb 16, 2021

SELL
$11.12 - $16.4 $2.11 Million - $3.11 Million
-189,592 Reduced 87.19%
27,850 $348,000
Q3 2020

Nov 16, 2020

SELL
$15.05 - $23.54 $834,372 - $1.31 Million
-55,440 Reduced 20.32%
217,442 $3.27 Million
Q2 2020

Aug 14, 2020

BUY
$12.7 - $30.73 $3.22 Million - $7.8 Million
253,859 Added 1334.48%
272,882 $6.69 Million
Q1 2020

May 15, 2020

BUY
$9.85 - $22.27 $187,376 - $423,642
19,023 New
19,023 $270,000

Others Institutions Holding CUE

About Cue Biopharma, Inc.


  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $43.2M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.